Diaceutics

Peter Kim, former Merck Research Laboratories president, will return to his alma mater Stanford University as a professor of biochemistry at the School of Medicine.

Diaceutics, CAHG Launch Personalized Rx-Focused Marketing, Educational Firm Bioceutics

Labceutics and Asuragen announced this week that that they will conduct an international, multi-center quality assurance study to track standardization across labs conducting BCR-ABL1 testing on the International Scale.

Amgen said this week that its $415 million proposed acquisition of Icelandic genetics research firm Decode will bolster its ability to evaluate which molecules to advance through its pipeline.

When inking companion diagnostic deals with drug developers, most test makers are trying to get beyond fee-for-service arrangements and strike more creative agreements with potential for bigger profits over a longer period of time.

FDA Approves Phase I Study Design for Cellceutix's Anti-Cancer Drug Kevetrin

By Turna Ray
Pharma may be increasingly investing in personalized medicine, but so far such molecularly-targeted treatments comprise a small slice of the industry's marketed products and revenues.

This article has been updated from a previous version to include information on the filing status of lumiracoxib in Europe, to clarify the current indication for nilotinib, and to correct information about the company's BCR-ABL development partners.

Pages

Thermo Fisher Scientific says it will no longer sell machines in China's Xinjiang region, according to the Wall Street Journal.

New Scientist reports that 20 percent of human and yeast proteins are uncharacterized.

The University of Zurich's Ruedi Aebersold and his colleagues analyzed a dozen HeLa cell lines to find differences in gene expression, protein levels, and more.

In Nature this week: protein-coding variants associated with body-fat distribution, and more.